|
Market Closed -
Nasdaq
05:00:01 21/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 166.43 USD | -0.06% |
|
-0.98% | +35.60% |
| 11-20 | Mizuho Securities Adjusts Gilead Sciences Price Target to $182 From $170, Maintains Outperform Rating | MT |
| 11-20 | Scientists are learning more about the rare Ebola virus in Congo outbreak | RE |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 206,430 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 35.56% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 227,476 | 218,041 | 208,094 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 34.14% | -4.15% | -4.56% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -39.1x | 20x | 18.7x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 15.8x | 10.8x | 7.95x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 2.56x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 6.58x | 6.14x | 5.92x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 7.25x | 6.49x | 5.97x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 45.7x | 11.8x | 11.3x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 98x | 13.2x | 12x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | 58.1x | 16.2x | 15x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | 1.72% | 6.19% | 6.66% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.297 | 3.376 | 3.094 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 1.98% | 2.03% | 1.86% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -4.252 | 8.303 | 8.91 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -77.5% | 40.7% | 34.7% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 31,383 | 33,603 | 34,852 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 4,982 | 18,414 | 18,486 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 2,321 | 16,473 | 17,328 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -5,292 | 10,697 | 11,301 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 21,047 | 11,612 | 1,664 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 166.43 | 166.43 | 166.43 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,240,339 | - | - |
| Announcement Date | 2/2/22 | 2/2/23 | 7/2/24 | 12/2/25 | 11/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -39.16x | 7.25x | 45.68x | 1.98% | 206B | ||
| 39.52x | 13.4x | 28.41x | 0.5% | 1,200B | ||
| 36.48x | 6.57x | 18.48x | 1.99% | 651B | ||
| 36.15x | 8.33x | 17.22x | 2.43% | 506B | ||
| 21.54x | 5.2x | 13.03x | 2.51% | 377B | ||
| 94.27x | 5.43x | 23.16x | 2.56% | 330B | ||
| 22.77x | 5.51x | 13.41x | 2.89% | 288B | ||
| 22.87x | 4.6x | 13.08x | 1.92% | 272B | ||
| 22.66x | 7.01x | 12.88x | 2.3% | 236B | ||
| 11.47x | 4.12x | 8.47x | 4.29% | 171B | ||
| Average | 26.86x | 6.74x | 19.38x | 2.34% | 424B | |
| Weighted average by Cap. | 33.20x | 8.26x | 20.94x | 1.88% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
















